Stojsic J.,Institute for Pulmonary Diseases and Tuberculosis |
Radojicic J.,Institute for Pulmonary Diseases and Tuberculosis |
Markovic J.,Institute for Pulmonary Diseases and Tuberculosis |
Milenkovic B.,Institute for Pulmonary Diseases and Tuberculosis |
And 3 more authors.
Journal of B.U.ON. | Year: 2010
Purpose: To find out the trends of distribution in different histological types of lung cancer in both genders in a period of 20 years. Methods: The most frequent histological types of lung cancer in tissue specimens obtained by bronchoscopy or percutaneous needle biopsy were analysed in terms of age and gender. The studied population included 6289 patients (16.6% females and 83.1% males). Statistical significance was established by x2 test at the level p<0.05. Results: Squamous cell carcinoma (SCC) prevailed in the total number of patients in all investigated years (58.0%), and separately in male (60.4%) and female (45.7%) patients. This histological type was predominant in all age groups in both genders (41.6% in males and 38.1 % in females). Conclusion: SCC has the highest incidence in Serbia. Continuous campaign against smoking and helping its cessation, improving working and socioeconomic conditions is a strategy for decreasing all histological types of lung cancer patients. © 2010 Zerbinis Medical Publications.
Ivanisevic J.,University of Belgrade |
Kotur-Stevuljevic J.,University of Belgrade |
Stefanovic A.,University of Belgrade |
Jelic-Ivanovic Z.,University of Belgrade |
And 4 more authors.
Clinical Biochemistry | Year: 2012
Objectives: Sarcoidosis is an inflammatory disease characterised by enhanced production of reactive oxygen species and alterations in the circulating lipid profile. Both attributes are thought to play a role in its pathogenesis. However, current knowledge regarding the significance of blood oxidative stress/anti-oxidant defence as well as alterations in lipid status parameters in sarcoidosis is scarce. The aim of our study was to assess these parameters and their inter-relationships, as well as their potential for patient-control discrimination. Design and methods: Oxidative stress status and anti-oxidant defence parameters were determined in serum and erythrocytes and lipid status parameters were assessed in the serum of 213 treated sarcoidosis patients and 90 controls. Results: Malondialdehyde, superoxide anion, total oxidant status, prooxidant-antioxidant balance and triglycerides were significantly higher whereas total anti-oxidant status, superoxide dismutase activity and HDL-cholesterol were significantly lower in sarcoidosis patients compared with controls. Total sulfhydryl group content was higher in patients compared with controls. Serum and erythrocyte malondialdehyde exhibited the strongest ability to predict disease presence. Elevated oxidative stress was characterised by higher clinical accuracy compared with lipid status abnormality. Some oxidative stress and lipid status markers were significantly associated in sarcoidosis. Conclusions: Sarcoidosis is characterised by increased oxidative stress, diminished overall anti-oxidative protection and alterations in the circulating lipid profile. Both oxidative stress and lipid status parameters demonstrated the potential to discriminate sarcoidosis from controls which was particularly evident from the point of view of oxidative stress status parameters. Association between these parameters may indicate an increased risk for atherosclerosis development. © 2012 The Canadian Society of Clinical Chemists.
Vukic V.,Clinical Hospital Center Bezanijska kosa |
Skodric-Trifunovic V.,Institute for Pulmonary Diseases and Tuberculosis |
Gvozdenovic B.S.,AbCRO Inc |
Jovanovic D.,Institute for Pulmonary Diseases and Tuberculosis |
Djuric D.,University of Kragujevac
Srpski Arhiv za Celokupno Lekarstvo | Year: 2010
Introduction: Lung cancers are mostly detected in the developed clinical stages, with clearly manifested pulmonary, extrapulmonary or metastatic manifestations. In the early disease stages, radiographic and clinical manifestations may be absent or mimicked. Objective: The aim of this study was the timely detection of early pulmonary, extrapulmonary and paraneoplastic manifestations of lung cancers in order to apply the most appropriate treatment protocols. Methods: We examined 230 patients with lung cancer, among them 125 of the working study group with minimal pulmonary and/or initial paraneoplastic symptoms, and 105 patients in the control group with clear tumour manifestations. Results: The symptom analysis revealed a statistically significantly lesser presence of the respiratory symptoms in the working study group (68%) in comparison with the control group of patients (97%) (χ2=29.996; p<0.001). The analysis of radiographic presentations of lung cancer showed that there were significantly more patients with normal findings in the working group (6.4%) than in the control group - 1.9% (p>0.05), and a positive bronchoscopic finding of the centrally localized tumour (mainly right upper lobe) was confirmed in patients of both groups with normal radiographic findings. The number of diagnosed patients in earlier clinical disease stages (I, II, IIIa) with better prognosis in non-small cell lung cancer was significantly higher (χ2=19.149; p<0.001) in the working group (71.1%) in comparison with the control group (38.1%). Small cell lung cancer was more frequently diagnosed in the stage of limited disease in the working (80%) than in the control group (38.1%) (χ2=10.039; p<0.05). With regard to treatment administration, there is a statistically significant difference (χ2=4.013; p=0.0452) in the frequency between the use of chemotherapy and highly significant difference (χ2=22.044; p<0.001) in the frequency of use of surgical treatment in the working group in comparison with the control group - both chemotherapy and surgery treatment were more frequent in the patients of the working group. Conclusion: Recognizing the initial pulmonary, extrapulmonary or paraneoplastic manifestations as well as performing diagnostic procedures in due time represent the most important guidelines in early detection and the most efficacious therapeutic choice in lung cancer.